These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28187280)

  • 21. I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.
    Printz C
    Cancer; 2013 Jun; 119(11):1925-7. PubMed ID: 23695808
    [No Abstract]   [Full Text] [Related]  

  • 22. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 23. Facilitating patient-centered cancer research and a new era of drug discovery.
    Niederhuber JE
    Oncologist; 2009 Apr; 14(4):311-2. PubMed ID: 19365096
    [No Abstract]   [Full Text] [Related]  

  • 24. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. That's how you make drugs!
    Kapitein P
    Chin Clin Oncol; 2016 Dec; 5(6):82. PubMed ID: 27334463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Targeted drugs a chance for a better cure].
    Bergh J; Jonsson B
    Lakartidningen; 2010 Apr 21-27; 107(16):1071-4. PubMed ID: 20476704
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical setbacks for toll-like receptor 9 agonists in cancer.
    Schmidt C
    Nat Biotechnol; 2007 Aug; 25(8):825-6. PubMed ID: 17687345
    [No Abstract]   [Full Text] [Related]  

  • 28. Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions.
    Rahman NA; Ison G; Beaver JA
    Clin Pharmacol Ther; 2020 Sep; 108(3):419-421. PubMed ID: 32640034
    [No Abstract]   [Full Text] [Related]  

  • 29. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highlights in cancer care 2007. 10 notable developments and events in cancer research and care.
    Oncology (Williston Park); 2007 Dec; 21(14):1758. PubMed ID: 18247020
    [No Abstract]   [Full Text] [Related]  

  • 32. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 33. Recasting cancer trials.
    Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
    [No Abstract]   [Full Text] [Related]  

  • 34. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.
    Yauch RL; Settleman J
    Curr Opin Genet Dev; 2012 Feb; 22(1):45-9. PubMed ID: 22321987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical medicine. Biomarker tests need closer scrutiny, IOM concludes.
    Kaiser J
    Science; 2012 Mar; 335(6076):1554. PubMed ID: 22461579
    [No Abstract]   [Full Text] [Related]  

  • 37. CANCER RESEARCH. Brazil bill would legalize renegade cancer pill.
    Escobar H
    Science; 2016 Apr; 352(6281):18. PubMed ID: 27034350
    [No Abstract]   [Full Text] [Related]  

  • 38. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enrichment designs: efficiency in development of cancer treatments.
    Temple RJ
    J Clin Oncol; 2005 Aug; 23(22):4838-9. PubMed ID: 15983397
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical endpoints in trials of drugs for cancer: time for a rethink?
    Koopmans PP
    BMJ; 2002 Jun; 324(7350):1389-91. PubMed ID: 12052814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.